化合物 (-)-Cevimeline hydrochloride hemihydrate|T13421|TargetMol

(-)-Cevimeline hydrochloride hemihydrate

￥34800 25mg 起订

上海更新日期：2024-12-02

TargetMol中国（陶术生物）

VIP1年

联系人：邵小姐

手机：15002134094 拨打

邮箱：marketing@targetmol.cn

产品详情:

中文名称：: 化合物 (-)-Cevimeline hydrochloride hemihydrate

英文名称：: (-)-Cevimeline hydrochloride hemihydrate

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

产品类别：: 抑制剂

货号：: T13421

Product Introduction

Bioactivity

Name	(-)-Cevimeline hydrochloride hemihydrate
Description	Cevimeline hydrochloride hemihydrate ((-)-SNI-2011), a novel muscarinic receptor agonist, is being explored as a potential treatment for xerostomia in Sjogren's syndrome, exhibiting an IC50 value indicative of its affinity for mAChR. This compound's pharmacological effects on the gastrointestinal, urinary, and reproductive systems, alongside its impact on various tissues, were thoroughly examined in species including mice, rats, guinea pigs, rabbits, and dogs. The metabolic breakdown of (-)-SNI-2011 was studied in vitro using rat and dog liver microsomes to assess its biotransformation. Upon oral administration, peak plasma concentrations were reached within an hour in both rats and dogs, showcasing rapid absorption and a subsequent decrease in concentration with a half-life ranging from 0.4 to 1.1 hours. Bioavailability was noted at 50% in rats and 30% in dogs. Metabolic pathways highlighted significant species differences, with both S- and N-oxidized metabolites identified in rats, but only N-oxidized metabolites in dogs. Additionally, gender differences in pharmacokinetics were observed in rats but were absent in dogs. In vitro studies pinpointed the involvement of cytochrome P450 (CYP) and flavin-containing monooxygenase (FMO) in the metabolism of (-)-SNI-2011, specifically through sulfoxidation and N-oxidation processes, respectively. CYP2D and CYP3A were identified as the primary enzymes responsible for sulfoxidation in rat liver microsomes.
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Keywords	Cevimeline Hydrochloride \| ( ) Cevimeline hydrochloride hemihydrate \| AF102B Hydrochloride \| SNI2011 \| ()Cevimeline hydrochloride hemihydrate \| SNI 2011 \| AF102B hydrochloride Hemihydrate \| SNI-2011 \| Cevimeline hydrochloride Hemihydrate
Inhibitors Related	Crizotinib \| RepSox \| Ceritinib \| A 83-01 \| Lorlatinib \| ALK-IN-1 \| EML4-ALK kinase inhibitor 1 \| Alectinib hydrochloride \| SB-431542 \| LDN-193189 2HCl \| Brigatinib \| DMH-1

(-)-SNI-2011|||(-)-AF102B hydrochloride hemihydrate|TargetMol

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期	(12年)
注册资本	589.8595万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,工厂,试剂,定制,服务
主营行业	中间体,天然产物,生物化工,化学试剂,生物技术服务